Screener
Prime Medicine PRME Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows provided by financing activities: | ||
| Net proceeds from stock option exercises | 416 | — |
| Proceeds from ESPP offerings | 338 | 197 |
| Proceeds from research and development funding liability | — | 6,000 |
| Net cash provided by financing activities | 754 | 6,197 |
| Net change in cash, cash equivalents, and restricted cash | (15,581) | (129,043) |
| Cash, cash equivalents, and restricted cash at beginning of period | 76,723 | 196,538 |
| Cash, cash equivalents, and restricted cash at end of period | $61,142 | $67,495 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's net change in cash?
- Prime Medicine (PRME) reported net change in cash of -$16.66M in Q2 2026.
- How has Prime Medicine's net change in cash changed year-over-year?
- Prime Medicine's net change in cash increased by 56.7% year-over-year, from -$38.44M to -$16.66M.
- What is the long-term trend for Prime Medicine's net change in cash?
- Over 2 years (2021 to 2023), Prime Medicine's net change in cash has grown at a -4.9% compound annual growth rate (CAGR), from $161.57M to -$146.05M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Prime Medicine's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude